FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	OVAL							
	OMB Number:	3235-0287							
	Estimated average burden								
l	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*							2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC [									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>LEHMAN LEAH M</u>						bpa]										Direc	ctor	10	)% O	wner	
(1 - 1) (5 in 1) (15 in 1)															X	Office			ther ( elow)	specify	
(Last) (First) (Middle)							3. Date of Earliest Transaction (Month/Day/Year)									VI	P, Clinical 8	& Reg. Af	fairs		
111 BARCLAY BLVD						11/30/2004												J			
SUITE 280																					
						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)															X	Form filed by One Reporting Person					
LINCOL	NSHIRE II		50069													Form filed by More than One Reporting					
																Person				, turing	
(City)	(St	ate) (	Zip)																		
		Tabl	e I - Noi	n-Deriv	ative	Se	curitie	s Acc	quired,	Dis	posed o	f, or	Ben	eficia	lly (	Owne	ed				
1. Title of S	Security (Inst	r. 3)		2. Transa	ction					3. 4. Securities Acquired (A)								6. Ownership		7. Nature	
				Date (Month/D	av/Yea			xecution Date,		Transaction Code (Instr.				3, 4 an				Form: Dire (D) or Indir		of Indirect Beneficial	
				(		(Month/Day/Yea		ay/Year)							Owr		d Following	(l) (Instr. 4)		Ownership (Instr. 4)	
										v	Amount	(	A) or D)	Price	- 1	Reported Transaction(s)				(111301. 4)	
									Code	Ľ	Amount	(	D)	1 1100		(Instr.	3 and 4)				
Common Stock 11/30/2						2004					50,000	)	D \$10.		07 109,777		D				
		Та	ble II - I	Derivati	ive S	ecu	rities	Acqu	ired, D	ispo	sed of,	or B	enefi	cially	/ Ov	ned					
											onvertib										
1. Title of Derivative	2. Conversion	3. Transaction Date	3A. Deem Execution		4. Transactio		5. Number on of		6. Date E		sable and	7. Title and Amount of				ice of 9. Number		of 10. Ownership	hin	11. Nature of Indirect	
Security	or Exercise Price of Derivative	(Month/Day/Year)	if any	· [	Code (				(Month/Day/Year) S			Securities			Security (Instr. 5)		Securities Beneficially Owned	Form:	٠.	Beneficial	
(Instr. 3)			(Month/Da	ay/Year)	8)								Underlying Derivative					Direct (		Ownership (Instr. 4)	
Security						(A) or Disposed of (D)		Security (Instr. and 4)				str. 3	3		Following Reported	(I) (Inst		, ,			
															Transaction(	(s)					
							(Instr. 3, 4 and 5)									(Instr. 4)					
			F			anu s)		Т				1.		-							
													Am   or	ount							
									Date		Expiration		Nur	nber							
			- 1	Code	v	(A)	(D)	Exercisa		Date	Title		res								

**Explanation of Responses:** 

/s/ Leah M. Lehman, Ph.D. 11/30/2004

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.